These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 29998419)

  • 1.
    Dizdarevic S; Jessop M; Begley P; Main S; Robinson A
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline quality of life predicts overall survival in patients with mCRPC treated with
    Frantellizzi V; De Feo MS; Di Rocco A; Pontico M; Pani A; Farcomeni A; Cosma L; Lazri J; De Vincentis G
    Hell J Nucl Med; 2020; 23(1):12-20. PubMed ID: 32222727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen flare induced by
    Castello A; Macapinlac HA; Lopci E; Santos EB
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2256-2263. PubMed ID: 29785515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with
    Frantellizzi V; Farcomeni A; Follacchio GA; Pacilio M; Pellegrini R; Pani R; De Vincentis G
    Ann Nucl Med; 2018 Feb; 32(2):142-148. PubMed ID: 29285670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
    Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
    Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study.
    Frantellizzi V; Monari F; Mascia M; Costa R; Rubini G; Spanu A; Farcomeni A; Lodi Rizzini E; Cindolo L; Licari M; Lavelli V; Nuvoli S; Ricci M; Dionisi V; Nappi AG; De Vincentis G
    Int J Radiat Biol; 2020 Dec; 96(12):1608-1613. PubMed ID: 33074066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Matsubara N; Kinuya S; Hosono M; Yajima Y; Doi T
    Int J Clin Oncol; 2017 Oct; 22(5):954-963. PubMed ID: 28478485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
    Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
    Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
    Sartor O; Coleman RE; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Vogelzang NJ; Bruland Ø; Kobina S; Wilhelm S; Xu L; Shan M; Kattan MW; Parker C
    Ann Oncol; 2017 May; 28(5):1090-1097. PubMed ID: 28453701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes of radium-223 therapy for metastatic castration-resistant prostate cancer following national health insurance reimbursement in Taiwan.
    Yao SF; Huang WJ; Wei TC; Wang YF; Lin KH; Hu LH; Ting CH; Lee TH; Yeh SH; Peng NJ
    J Chin Med Assoc; 2024 Jul; 87(7):734-740. PubMed ID: 38771079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer.
    Jadvar H; Challa S; Quinn DI; Conti PS
    Cancer Biother Radiopharm; 2015 Jun; 30(5):195-9. PubMed ID: 25746633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer.
    Kuppen MC; Westgeest HM; van der Doelen MJ; van den Eertwegh AJ; Coenen JL; Aben KK; van den Bergh AC; Bergman AM; den Bosch JV; Celik F; Hendriks MP; Lavalaye J; der Meer SV; Polee MB; Somford DM; van Oort IM; Uyl-de Groot CA; Gerritsen WR
    Future Oncol; 2020 Jul; 16(19):1371-1384. PubMed ID: 32469606
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-world safety and effectiveness of radium-223 in patients with metastatic castration-resistant prostate cancer: Interim analyses of the prospective, observational RAPIT study.
    Huang CY; Huang CP; Huang YY; Huang SK; Lu K; Huang WJ; Meng E; Huang SP; Lee MY; Chen F; Pang ST
    Int J Cancer; 2024 Oct; 155(7):1268-1277. PubMed ID: 38924042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing Radiographic Response to
    Anand A; Trägårdh E; Edenbrandt L; Beckman L; Svensson JH; Thellenberg C; Widmark A; Kindblom J; Ullén A; Bjartell A
    J Nucl Med; 2020 May; 61(5):671-675. PubMed ID: 31586004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Prognostic Value of Quantitative Bone SPECT/CT Before
    Dittmann H; Kaltenbach S; Weissinger M; Fiz F; Martus P; Pritzkow M; Kupferschlaeger J; la Fougère C
    J Nucl Med; 2021 Jan; 62(1):48-54. PubMed ID: 32444369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride: A Possible Abscopal Effect?
    Kwee SA; Lim J; Coel MN
    Clin Nucl Med; 2017 Nov; 42(11):868-871. PubMed ID: 28872544
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Fosbøl MØ; Petersen PM; Kjaer A; Mortensen J
    J Nucl Med; 2018 Apr; 59(4):596-602. PubMed ID: 28864632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel nomogram developed for determining suitability of metastatic castration-resistant prostate cancer patients to receive maximum benefit from radium-223 dichloride treatment-Japanese Ra-223 Therapy in Prostate Cancer using Bone Scan Index (J-RAP-BSI) Trial.
    Kitajima K; Igeta M; Kuyama J; Kawahara T; Suga T; Otani T; Sugawara S; Kono Y; Tamaki Y; Seko-Nitta A; Ishiwata Y; Ito K; Toriihara A; Watanabe S; Hosono M; Miyake H; Yamamoto S; Narita M; Daimon T; Yamakado K
    Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1487-1498. PubMed ID: 36539508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.